Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Covid-19 Data Analyses in BrazilCompleted
NCT06652451N/AUpdated Sep 18, 2025
Sponsor: AstraZeneca
Covid
Brazil
REACT - REAl Care for AsThma - A Disease Study to Identify Patients With Severe Uncontrolled AsthmaTerminated
NCT06299306N/AUpdated Sep 18, 2025
Sponsor: AstraZeneca
Asthma, Bronchial
Germany
UNFOLD Study EgyptCompleted
NCT06188494N/AUpdated Sep 18, 2025
Sponsor: AstraZeneca
Breast Cancer
Egypt
Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.Completed
NCT06590740Phase 4Updated Sep 18, 2025
Sponsor: AstraZeneca
Cough-Variant Asthma
China
NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer PatientsCompleted
NCT06131424N/AUpdated Sep 18, 2025
Sponsor: AstraZeneca
HER2-negative
Argentina, Brazil, Dominican Republic, Hong Kong, India +8 more
Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in RussiaTerminated
NCT06338839N/AUpdated Sep 18, 2025
Sponsor: AstraZeneca
Transthyretin Amyloidosis Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Russia
Characterizing the Human Airway Immune Response to FluMist VaccinationRecruiting
NCT07177417Phase 4Updated Sep 17, 2025
Sponsor: Washington University School of Medicine
Healthy Young Adults · Influenza Vaccines · Influenza Vaccine Response
United States
ALG-LungCancerRegistry (SAFRO2202)Recruiting
NCT07161882N/AUpdated Sep 16, 2025
Sponsor: Société Algérienne de Formation et de Recherche en Oncologie
Lung Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell · Carcinoid Tumor
Algeria
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesNot Yet Recruiting
NCT07175415Phase 1, Phase 2Updated Sep 16, 2025
Sponsor: Princess Maxima Center for Pediatric Oncology
Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer PatientsCompleted
NCT03019003Phase 1Updated Sep 16, 2025
Sponsor: Massachusetts General Hospital
Head and Neck Cancer
United States
Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).Completed
NCT05219162Phase 4Updated Sep 11, 2025
Sponsor: AstraZeneca
Advanced NSCLC
China
Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion AdministrationRecruiting
NCT05557487N/AUpdated Sep 10, 2025
Sponsor: Gee-Chen Chang
Lung Cancer · High-Risk Cancer · Smoking · Pollution; Exposure
Taiwan
A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy ParticipantsCompleted
NCT06138795Phase 1Updated Sep 9, 2025
Sponsor: AstraZeneca
Healthy Participants
United States
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal CancerActive Not Recruiting
NCT02962063Phase 1, Phase 2Updated Sep 5, 2025
Sponsor: Memorial Sloan Kettering Cancer Center
Esophageal Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
United States
A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female ParticipantsCompleted
NCT06547164Phase 1Updated Sep 4, 2025
Sponsor: AstraZeneca
Healthy Participants
United Kingdom
Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.Completed
NCT03085225Phase 1Updated Sep 4, 2025
Sponsor: Institut Bergonié
Ovarian Carcinoma · Soft Tissue Sarcoma
France
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With AsthmaCompleted
NCT06644924Phase 2Updated Sep 3, 2025
Sponsor: AstraZeneca
Asthma
United States
A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisCompleted
NCT05364931Phase 2Updated Sep 3, 2025
Sponsor: AstraZeneca
Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
United States, Argentina, Australia, Austria, Canada +15 more
FASENRA SCEI for Long-term UseCompleted
NCT03588546N/AUpdated Sep 2, 2025
Sponsor: AstraZeneca
Asthma
Japan
Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient InvestigationCompleted
NCT04872621N/AUpdated Sep 2, 2025
Sponsor: AstraZeneca
Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)
Japan
Anti-thrombotic and Glucose Lowering Therapy in Diabetic Patients Undergoing PCICompleted
NCT04481997N/AUpdated Aug 29, 2025
Sponsor: Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA
Type2 Diabetes Mellitus · Coronary Heart Disease
Portugal
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic SarcomaCompleted
NCT04076579Phase 2Updated Aug 29, 2025
Sponsor: University of Michigan Rogel Cancer Center
Sarcoma · Sarcoma Metastatic
United States
An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.Completed
NCT05492877Phase 2Updated Aug 29, 2025
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
United States, Argentina, Bulgaria, Canada, Denmark +9 more
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced CancerCompleted
NCT04564027Phase 2Updated Aug 29, 2025
Sponsor: AstraZeneca
Advanced Solid Tumours
United States, France, Spain
Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled CorticosteroidsTerminated
NCT04643158Phase 2Updated Aug 28, 2025
Sponsor: AstraZeneca
Asthma
Australia, Canada, Germany, Hungary, Poland +5 more

Previous page Next page